FDA Approves Merck’s Keytruda as Adjuvant Treatment for Adult and Pediatric Patients With Stage IIB or IIC Melanoma Following Complete Resection
The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection. Additionally, the FDA expanded the indication for Keytruda as adjuvant treatment for stage III melanoma following complete resection to include pediatric patients (12 years and older).